skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

Case Series

(2009) Views  (707) Full article downloads

Authors: Jane S Myung, Grant D Aaker, Szilárd Kiss

Published Date December 2010 Volume 2010:4 Pages 1423 - 1426
DOI: http://dx.doi.org/10.2147/OPTH.S15696

Jane S Myung, Grant D Aaker, Szilárd Kiss
Department of Ophthalmology, Weill Cornell Medical Center, New York, NY, USA

Purpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis.
Methods: A retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed.
Results: Six eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period.
Conclusions: In patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.

Keywords: corticosteroids, dexamethasone implant, Ozurdex, uveitis




 

Other articles by Dr Szilard Kiss



Readers of this article also read:

Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
Pregabalin for the management of fibromyalgia syndrome
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Bacterial conjunctivitis
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
Pharmacological enhancement of treatment for amblyopia